UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 12, 2006
Date of Report (Date of Earliest Event Reported)
ALLERGAN, INC.
(Exact Name of Registrant as Specified in its Charter)
| |
|
|
|
|
Delaware
(State of Incorporation)
|
|
1-10269
(Commission File Number)
|
|
95-1622442
(IRS Employer
Identification Number) |
2525 Dupont Drive
Irvine, California 92612
(Address of Principal Executive Offices) (Zip Code)
(714) 246-4500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On April 12, 2006, Allergan, Inc. (“Allergan”) issued a press release announcing the
completion of its previously announced concurrent private placements of $750,000,000 aggregate
principal amount of 1.50% Convertible Senior Notes due 2026 and $800,000,000 aggregate principal
amount of 5.75% Senior Notes due 2016. Allergan also announced that
it will redeem the entire outstanding principal amount
of its Zero Coupon Senior Convertible Notes due 2022 on May 15, 2006. A copy of the press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) |
|
Exhibits. |
| |
| 99.1 |
|
Allergan, Inc. press release dated April 12, 2006. |